Choice Institutional Equities has reiterated its 'BUY' recommendation for Jeena Sikho Lifecare Ltd, a smallcap company with a market capitalization exceeding ₹6,300 crore. The brokerage firm projects a substantial 96% upside potential for the stock, setting a 12-month target price of ₹1,000.
Ambitious Expansion in Ayurveda Ecosystem
The positive outlook stems from Jeena Sikho Lifecare's strategic focus on expanding its Ayurveda ecosystem. Management aims to scale up to between 7,000 and 10,000 operational beds over the next three to five years, utilizing a capital-efficient expansion model. This growth strategy also includes deepening its preventive care offerings and broadening its wellness and product portfolio.
Strong Financial Growth Projections
Choice Institutional Equities anticipates robust financial performance from Jeena Sikho Lifecare. The brokerage forecasts impressive compound annual growth rates (CAGR) for the period of FY26-FY29:
- Revenue: 33.6%
- EBITDA: 34.9%
- PAT (Profit After Tax): 39.4%
Furthermore, the company is guiding for approximately 30% annual revenue growth and expects to achieve a balanced 50:50 mix between services and products. Management projects a significant 4-5 times increase in profit after tax over the same timeframe.
Healthy Margin Expectations
The brokerage report highlights management's expectation to sustain strong profitability margins. Jeena Sikho Lifecare aims for an EBITDA margin exceeding 40% and a PAT margin between 27% and 30%. These figures underscore the company's commitment to efficient operations and strong financial health.
Valuation and Target Price
Choice's target price of ₹1,000 for Jeena Sikho Lifecare is based on a discounted cash flow (DCF) valuation. With the stock assessed at ₹510, the target implies an upside potential of approximately 96%. The valuation also translates to a price-to-earnings (PE) multiple of 28 times based on FY28 estimated earnings per share (EPS), with a PEG ratio of 0.8 times, indicating attractive growth at a reasonable price.